Ono Pharmaceutical Co. Ltd: Gastrointestinal Stromal Tumors trials
The registry lists 10 Gastrointestinal Stromal Tumors studies with Ono Pharmaceutical Co. Ltd as lead sponsor. 2 are open to participants now and 2 have results posted.
Phase 1 6Phase 2 3Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of DCC-2618 in Patients With GIST After at Least 3 Prior TreatmentsRecruitingNCT07618377Phase 1
- A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)RecruitingNCT06630234Phase 1/2
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibActive, not recruitingNCT03673501Phase 3Results posted
- Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer TherapiesCompletedNCT03353753Phase 3Results posted
- A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesActive, not recruitingNCT05957367Phase 1/2
- A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibActive, not recruitingNCT05734105Phase 3
- Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT05080621Phase 1/2
- A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GISTCompletedNCT04530981Phase 1
- Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GISTApproved for marketingNCT04148092
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1